Sector News

Regeneron tops best science employer poll again

October 17, 2014
Life sciences
Regeneron has once again come top of Science magazine’s top 20 employers survey, followed by Novo Nordisk and Roche’s Genentech unit.
 
The poll is based on 5,394 responses from readers of Science and employees in the biotechnology and pharmaceutical industry, who were asked to rank the best employers on a number of characteristics. The categories included ‘’innovative leader in the industry’, treats employees with respect’, ‘has loyal employees’ and ‘is socially responsible’.
 
Regeneron came out as the top company for the third year in a row, while Novo leapt to second from 11th place last year. They were followed by Genentech, Vertex (4), Eli Lilly (5), AbbVie (7) and Roche itself, up eight places from last year to eighth.
 
Biogen Idec came in at 10th, while Novartis slipped three places to 11th. Newcomers to the list were Actelion (14), Johnson & Johnson (19) and Merck KGaA (20). The other pharma players in the top 20 are Boehringer Ingelheim (13, down from 9), Celgene (up two places to 15), Bayer (up four to 16) and Amgen, which rose one place to 18th.
 
Science claims that “a common thread runs through the top 20 list: give employees the intellectual freedom and support necessary to pursue high-risk/high-reward goals – and they’ll deliver”. The journal says that by adding “a noble mission” to this, “employers can create a positive feedback loop that maximises employees’ drive and dedication as well as company profits”.
 
By Kevin Grogan
 

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach